The present invention refers to deuterated Baricitinib with improved metabolic stability, as a JAK1 and JAK2 inhibitor for use in treating a disease selected from rheumatoid arthritis; psoriasis; inflammation; myeloproliferative disorders such as chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia and primary myelofibrosis; autoimmune diseases including multiple sclerosis, lupus, diabetes type 1, myasthenia gravis, transplant rejection, myocarditis; alopecia and other hair loss disorders; dry eye; Sjogren syndrome; and other eye-related diseases.
展开▼
